Rewiring the solid tumor epigenome for cancer therapy

Expert Review of Anticancer Therapy

Volumn 16, Issue 9, 2016, Pages 977-987

  Braun, Christian J ^a,b   Hemann, Michael T ^a,b  

^a David H Koch Institute for Integrative Cancer Research   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer; chromatin; combination treatment; epigenetics; personalized medicine; solid tumors

Indexed keywords

ARGININE; AZACITIDINE; BELINOSTAT; BROMODOMAIN INHIBITOR; DECITABINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE INHIBITOR; HISTONE H2A; HISTONE H3; LYSINE; LYSINE ACETYLTRANSFERASE INHIBITOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PANOBINOSTAT; ROMIDEPSIN; TRICHOSTATIN A; TUMOR MARKER; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VORINOSTAT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CHROMOSOME; DNA MODIFICATION; EPIGENETIC CANCER THERAPY; EPIGENETICS; GENE MUTATION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC REGULATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HUMAN; NUCLEOSOME; PROTEIN EXPRESSION; REVIEW; RNA BINDING; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; GENETIC EPIGENESIS; GENETICS; HUMAN GENOME; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; GENOME, HUMAN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84985945344     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1080/14737140.2016.1212663     Document Type: Review

References (114)

1. A.Annunziato DNA packaging:nucleosomes and chromatin [Internet]. Nat Educ. 2008;1:1. [cited 2016 May 18]. Available from:http://www.nature.com/scitable/topicpage/dna-packaging-nucleosomes-and-chromatin-310.
2. Eissenberg JC, Elgin SCR. Heterochromatin and Euchromatin. In:eLS. Chichester:John Wiley & Sons; 2014. doi:10.1002/9780470015902.a0001164.pub3
3. C.D.Allis, D.Reinberg, M.-L.Capparos, et al. Epigenetics. 2nd ed. New York:Cold Spring Harbor Laboratory Press; 2015.•• Excellent epigenetics textbook for both students and professionals.
4. B.Jin, Y.Li, K.D.Robertson. DNA methylation:superior or subordinate in the epigenetic hierarchy? Genes Cancer [Internet]. 2011;2(6):607–617 [cited 2016 May 2]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3174260&tool=pmcentrez&rendertype=abstract
5. A.Zemach, I.E.McDaniel, P.Silva, et al. Genome-wide evolutionary analysis of eukaryotic DNA methylation. Science [Internet]. 2010;328(5980):916–919 [cited 2016 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20395474•• Groundbreaking work analyzing the DNA methylation patterns of plants, fungi, and animals by bisulfite sequencing.
6. A.V.Probst, E.Dunleavy, G.Almouzni. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol [Internet]. 2009;10(3):192–206 [cited 2016 Feb 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19234478
7. M.Okano, D.W.Bell, D.A.Haber, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell [Internet]. 1999;99(3):247–257 [cited 2014 Dec 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10555141
8. A.J.Bannister, T.Kouzarides. Regulation of chromatin by histone modifications. Cell Res [Internet]. 2011;21(3):381–395. doi:10.1038/cr.2011.22.
9. B.Xhemalce, M.A.Dawson, A.J.Bannister. Histone modifications. In Meyers RA, editor. Encyclopedia of molecular cell biology and molecular medicine:epigenetic regulation and epigenomics, 2nd edition. Weinheim:Wiley; 2011.
10. A.Eberharter, P.B.Becker. Histone acetylation:a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep [Internet]. 2002;(3)(3):224–229 [cited 2016 Mar 29]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1084017&tool=pmcentrez&rendertype=abstract• Comprehensive review about different states of chromatin compaction.
11. L.Zeng, M.M.Zhou. Bromodomain:an acetyl-lysine binding domain. FEBS Lett [Internet]. 2002;513(1):124–128 [cited 2016 Mar 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11911891
12. P.Filippakopoulos, S.Knapp. Targeting bromodomains:epigenetic readers of lysine acetylation. Nat Rev Drug Discov [Internet]. 2014;13(5):337–356 [cited 2016 Jan 12]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24751816
13. K.K.Lee, J.L.Workman. Histone acetyltransferase complexes:one size doesn’t fit all. Nat Rev Mol Cell Biol [Internet]. 2007;8(4):284–295. doi:10.1038/nrm2145.
14. C.Martin, Y.Zhang. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol [Internet]. 2005;6(11):838–849. doi:10.1038/nrm1761.
15. Q.Zhao, G.Rank, Y.T.Tan, et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol [Internet]. 2009;16(3):304–311. [cited 2016 Apr 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19234465
16. E.Guccione, C.Bassi, F.Casadio, et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature [Internet]. 2007;449(7164):933–937. [cited 2016 Apr 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17898714•• Highly relevant insights into the histone modification cross talk.
17. R.A.Copeland, M.E.Solomon, V.M.Richon. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov [Internet]. 2009;8(9):724–732. doi:10.1038/nrd2974.
18. H.Van Attikum, S.M.Gasser. The histone code at DNA breaks:a guide to repair? Nat Rev Mol Cell Biol [Internet]. 2005;6(10):757–765 [cited 2016 Apr 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16167054
19. H.Goto, Y.Tomono, K.Ajiro, et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem [Internet]. 1999;274(36):25543–25549 [cited 2016 Apr 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10464286
20. D.Fabbro, S.W.Cowan-Jacob, H.Moebitz. Ten things you should know about protein kinases:IUPHAR review 14. Br J Pharmacol [Internet]. 2015;172(11):2675–2700 [cited 2016 Apr 06]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25630872
21. C.Crosio, G.M.Fimia, R.Loury, et al. Mitotic phosphorylation of histone H3:spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol [Internet]. 2002;22(3):874–885 [cited 2016 Mar 27]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=133550&tool=pmcentrez&rendertype=abstract
22. G.J.Narlikar, R.Sundaramoorthy, T.Owen-Hughes. Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes. Cell [Internet]. 2013;154(3):490–503 [cited 2015 Sep 9]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3781322&tool=pmcentrez&rendertype=abstract• Provides an in-depth overview about energy-depending chromatin remodeling.
23. S.Ramachandran, S.Henikoff. Replicating nucleosomes. Sci Adv [Internet]. 2015;1(7) [cited 2016 May 2]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4530793&tool=pmcentrez&rendertype=abstract
24. I.Maze, K.-M.Noh, A.A.Soshnev, et al. Every amino acid matters:essential contributions of histone variants to mammalian development and disease. Nat Rev Genet [Internet]. 2014;15(4):259–271. doi:10.1038/nrg3673.
25. T.R.Cech, J.A.Steitz. The noncoding RNA revolution-trashing old rules to forge new ones. Cell [Internet]. 2014;157(1):77–94 [cited 2014 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24679528
26. M.A.Gama-Sosa, V.A.Slagel, R.W.Trewyn, et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res [Internet]. 1983;11(19):6883–6894 [cited 2016 Apr 29]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=326421&tool=pmcentrez&rendertype=abstract
27. A.P.Feinberg, B.Vogelstein. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature [Internet]. 1983;301(5895):89–92 [cited 2016 Feb 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6185846•• Heavily cited groundbreaking work about the concept of DNA hypomethylation in cancer.
28. R.E.Banks, P.Tirukonda, C.Taylor, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res [Internet]. 2006;66(4):2000–2011 [cited 2016 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16488999
29. J.Clavell, R.Bernabe, A.Baez. Epigenetic silencing of CDKN2A, p14(ARF) and CDKN2B and TR{beta}I in head and neck cancers. Cancer Res [Internet]. 2008;68(9_Supplement):4299 [cited 2016 May 2]. Available from: http://cancerres.aacrjournals.org/content/68/9_Supplement/4299.short
30. S.B.Baylin, J.E.Ohm. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer [Internet]. 2006;6(2):107–116. doi:10.1038/nrc1799.
31. S.A.Bert, M.D.Robinson, D.Strbenac, et al. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell [Internet; cited 2016 Apr 29] [cited 2016 Apr 29]. 2013;23(1):9–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23245995
32. A.P.Feinberg, C.W.Gehrke, K.C.Kuo, et al. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res [Internet]. 1988;48(5):1159–1161 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3342396
33. S.E.Goelz, B.Vogelstein, S.R.Hamilton, et al. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science [Internet]. 1985;228(4696):187–190 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2579435
34. A.P.Feinberg, B.Vogelstein. Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun [Internet]. 1983;111(1):47–54 [cited 2016 Feb 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6187346
35. J.Li, R.A.Harris, S.W.Cheung, et al. Genomic hypomethylation in the human germline associates with selective structural mutability in the human genome. PLoS Genet [Internet]. 2012;8(5):e1002692 [cited 2016 Apr 29]. Available from: http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1002692
36. F.Gaudet, J.G.Hodgson, A.Eden, et al. Induction of tumors in mice by genomic hypomethylation. Science [Internet]. 2003;300(5618):489–492 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12702876
37. M.Ehrlich. DNA hypomethylation in cancer cells. Epigenomics [Internet]. 2009;1(2):239–259 [cited 2016 Apr 18]. Available from: http://www.futuremedicine.com/doi/abs/10.2217/epi.09.33
38. T.Rikimaru, A.Taketomi, Y.Yamashita, et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology [Internet]. 2007;72(1–2):69–74 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18004079
39. Y.Minamiya, T.Ono, H.Saito, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer [Internet]. 2011;74(2):300–304 [cited 2016 Mar 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21466904
40. C.A.Krusche, P.Wülfing, C.Kersting, et al. Histone deacetylase-1 and −3 protein expression in human breast cancer:a tissue microarray analysis. Breast Cancer Res Treat [Internet]. 2005;90(1):15–23 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15770522
41. A.C.West, R.W.Johnstone. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest [Internet]. 2014;124(1):30–39 [cited 2015 May 25]. Available from: https://www.jci.org/articles/view/69738
42. R.Huether, L.Dong, X.Chen, et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun [Internet]. 2014;5:3630 [cited 2016 Mar 20]. Available from: http://www.nature.com/ncomms/2014/140408/ncomms4630/full/ncomms4630.html
43. H.Noushmehr, D.J.Weisenberger, K.Diefes, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell [Internet]. 2010;17(5):510–522 [cited 2014 Jul 16]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2872684&tool=pmcentrez&rendertype=abstract• Description of the glioma hypermethylation phenotype.
44. M.E.Figueroa, O.Abdel-Wahab, C.Lu, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell [Internet]. 2010;18(6):553–567 [cited 2016 Feb 17]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4105845&tool=pmcentrez&rendertype=abstract
45. S.Virani, S.Virani, J.A.Colacino, et al. Cancer epigenetics:a brief review. Ilar J [Internet]. 2012;53(3–4):359–369 [cited 2016 Apr 12]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4021643&tool=pmcentrez&rendertype=abstract
46. T.B.Tomasi, W.J.Magner, A.N.H.Khan. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother [Internet]. 2006;55(10):1159–1184. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16680460
47. R.Brown, E.Curry, L.Magnani, et al. Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer [Internet]. 2014;14(11):747–753 [cited 2016 May 2]. doi:10.1038/nrc3819.
48. R.Alelú-Paz. The progression of cancer and metastasis formation:an epigenetic hypothesis. J Med Hypotheses Ideas [Internet]. 2015;9(1):20–23 [cited 2016 Mar 14]. Available from: http://www.sciencedirect.com/science/article/pii/S2251729415000026
49. S.L.Gerson. MGMT:its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer [Internet]. 2004;4(4):296–307. doi:10.1038/nrc1319.
50. J.C.Hassel, A.Sucker, L.Edler, et al. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer [Internet]. 2010;103(6):820–826 [cited 2016 May 2]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2966614&tool=pmcentrez&rendertype=abstract
51. W.Wick, M.Weller, M.Van Den Bent, et al. MGMT testing–the challenges for biomarker-based glioma treatment. Nat Rev Neurol [Internet]. 2014;10(7):372–385 [cited 2016 Feb 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24912512
52. V.Birgisdottir, O.A.Stefansson, S.K.Bodvarsdottir, et al. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res [Internet]. 2006;8(4):R38 [cited 2016 May 2]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1779478&tool=pmcentrez&rendertype=abstract
53. P.C.Fong, D.S.Boss, T.A.Yap, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med [Internet]. 2009;361(2):123–134 [cited 2016 Feb 18]. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa0900212• Highly relevant work exploiting synthetic lethality for cancer treatment.
54. F.Sorm, J.Veselý. Effect of 5-aza-2ʹ-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma [Internet]. 1968;15(4):339–343 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/5684460
55. P.A.Jones, S.M.Taylor. Cellular differentiation, cytidine analogs and DNA methylation. Cell [Internet]. 1980;20(1):85–93 [cited 2016 Feb 22]. Available from: http://www.sciencedirect.com/science/article/pii/0092867480902378
56. J.K.Christman. 5-Azacytidine and 5-aza-2ʹ-deoxycytidine as inhibitors of DNA methylation:mechanistic studies and their implications for cancer therapy. Oncogene [Internet]. 2002;21(35):5483–5495 [cited 2016 Apr 29]. Available from: http://www.nature.com/onc/journal/v21/n35/full/1205699a.html
57. R.Abele, M.Clavel, P.Dodion, et al. The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol [Internet]. 1987;23(12):1921–1924 [cited 2016 Apr 29]. Available from: http://europepmc.org/abstract/MED/2449354
58. L.A.Cowan, S.Talwar, A.S.Yang. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics [Internet]. 2010;2(1):71–86 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22122748
59. M.Clavel, S.Monfardini, S.Fosså, et al. 5-Aza-2ʹ-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann Oncol [Internet]. 1992;3(5):399–400 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1377488
60. A.B.Kornblith, J.E.Herndon, L.R.Silverman, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial:a Cancer and Leukemia Group B study. J Clin Oncol [Internet]. 2002;20(10):2441–2452 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12011121
61. L.R.Silverman, E.P.Demakos, B.L.Peterson, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the cancer and leukemia group B. J Clin Oncol [Internet]. 2002;20(10):2429–2440 [cited 2016 Apr 12]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12011120
62. C.Khan, N.Pathe, S.Fazal, et al. Azacitidine in the management of patients with myelodysplastic syndromes. Ther Adv Hematol [Internet]. 2012;3(6):355–373 [cited 2016 Apr 29]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3627328&tool=pmcentrez&rendertype=abstract
63. H.I.Saba. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag [Internet]. 2007;3(5):807–817 [cited 2016 Apr 29]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2376088&tool=pmcentrez&rendertype=abstract
64. J.N.Lowder, P.Taverna, J.-P.J.Issa. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy? Epigenomics [Internet]. 2015;7(7):1083–1088 [cited 2016 Apr 29]. Available from: http://www.futuremedicine.com/doi/abs/10.2217/epi.15.66?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
65. E.Hatzimichael, T.Crook. Cancer epigenetics:new therapies and new challenges. J Drug Deliv [Internet]. 2013;2013:529312 [cited 2016 Mar 29]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3600296&tool=pmcentrez&rendertype=abstract
66. H.Carén, S.M.Pollard, S.Beck. The good, the bad and the ugly:epigenetic mechanisms in glioblastoma. Mol Aspects Med [Internet]. 2013;34(4):849–862 [cited 2016 Mar 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22771539
67. M.-F.Robert, S.Morin, N.Beaulieu, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet [Internet]. 2003;33(1):61–65. doi:10.1038/ng1068.
68. E.Winquist, J.Knox, J.-P.Ayoub, et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma:a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs [Internet]. 2006;24(2):159–167 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16502349
69. A.J.Davis, K.A.Gelmon, L.L.Siu, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 Weeks. Invest New Drugs [Internet]. 2003;21(1):85–97 [cited 2016 May 3]. Available from: http://link.springer.com/article/10.1023/A%3A1022976528441
70. B.Segura-Pacheco, C.Trejo-Becerril, E.Perez-Cardenas, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res [Internet]. 2003;9(5):1596–1603 [cited 2016 Apr 29]. Available from: http://clincancerres.aacrjournals.org/content/9/5/1596.long
71. M.Candelaria, D.Gallardo-Rincón, C.Arce, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol [Internet]. 2007;18(9):1529–1538 [cited 2016 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17761710
72. M.Haberland, R.L.Montgomery, E.N.Olson. The many roles of histone deacetylases in development and physiology:implications for disease and therapy. Nat Rev Genet [Internet]. 2009;10(1):32–42 [cited 2015 Jun 16]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3215088&tool=pmcentrez&rendertype=abstract
73. A.J.M.De Ruijter, A.H.Van Gennip, H.N.Caron, et al. Histone deacetylases (HDACs):characterization of the classical HDAC family. Biochem J [Internet]. 2003;370(Pt 3):737–749 [cited 2015 Sep 30]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1223209&tool=pmcentrez&rendertype=abstract
74. K.J.Falkenberg, R.W.Johnstone. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov [Internet]. 2014;13(9):673–691. doi:10.1038/nrd4360.
75. M.Yoshida, M.Kijima, M.Akita, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem [Internet]. 1990;265(28):17174–17179 [cited 2016 Apr 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2211619
76. G.S.Mack. To selectivity and beyond. Nat Biotechnol [Internet]. 2010;28(12):1259–1266 [cited 2016 Apr 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21139608
77. M.Mottamal, S.Zheng, T.L.Huang, et al. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules [Internet]. 2015;20(3):3898–3941 [cited 2016 Jan 5]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4372801&tool=pmcentrez&rendertype=abstract
78. H.-J.Kim, S.-C.Bae. Histone deacetylase inhibitors:molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res [Internet]. 2011;3(2):166–179 [cited 2016 Mar 24]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3056563&tool=pmcentrez&rendertype=abstract
79. E.Schraufstatter, H.Bernt. Antibacterial action of curcumin and related compounds. Nature [Internet]. 1949;164(4167):456 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18140450
80. R.Kuttan, P.C.Sudheeran, C.D.Josph. Turmeric and curcumin as topical agents in cancer therapy. Tumori [Internet]. 1987;73(1):29–31 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2435036
81. S.C.Gupta, S.Patchva, B.B.Aggarwal. Therapeutic roles of curcumin:lessons learned from clinical trials. Aaps J [Internet]. 2013;15(1):195–218 [cited 2015 May 20]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3535097&tool=pmcentrez&rendertype=abstract
82. S.M.Kooistra, K.Helin. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol [Internet]. 2012;13(5):297–311. doi:10.1038/nrm3327.
83. E.Metzger, M.Wissmann, N.Yin, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature [Internet]. 2005;437(7057):436–439 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16079795
84. Y.Wang, H.Zhang, Y.Chen, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell [Internet]. 2009;138(4):660–672 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19703393
85. E.C.Kauffman, B.D.Robinson, M.J.Downes, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog [Internet]. 2011;50(12):931–944 [cited 2016 May 1]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3315373&tool=pmcentrez&rendertype=abstract
86. S.Gray. Epigenetic cancer therapy. San Diego (CA):Academic press; 2015.•• Highly relevant textbook summarizing treatment concepts and clinical trials involving epigentic compounds.
87. J.R.Whetstine, A.Nottke, F.Lan, et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell [Internet]. 2006;125(3):467–481 [cited 2016 Feb 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16603238
88. R.J.Klose, K.Yamane, Y.Bae, et al. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature [Internet]. 2006;442(7100):312–316 [cited 2016 Apr 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16732292
89. Y.Tsukada, J.Fang, H.Erdjument-Bromage, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature [Internet]. 2006;439(7078):811–816 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16362057
90. P.A.C.Cloos, J.Christensen, K.Agger, et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature [Internet]. 2006;442(7100):307–311 [cited 2016 Apr 7]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16732293
91. B.D.Fodor, S.Kubicek, M.Yonezawa, et al. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev [Internet]. 2006;20(12):1557–1562 [cited 2016 May 1]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1482475&tool=pmcentrez&rendertype=abstract
92. S.Sainathan, S.Paul, S.Ramalingam, et al. Histone demethylases in cancer. Curr Pharmacol Rep [Internet]. 2015;1(4):234–244 [cited 2016 May 1]. Available from: http://link.springer.com/10.1007/s40495-015-0025-y
93. M.K.Jang, K.Mochizuki, M.Zhou, et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell [Internet]. 2005;19(4):523–534 [cited 2016 Apr 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16109376
94. J.You, Q.Li, C.Wu, et al. Regulation of aurora B expression by the bromodomain protein Brd4. Mol Cell Biol [Internet]. 2009;29(18):5094–5103. [cited 2016 May 3]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2738288&tool=pmcentrez&rendertype=abstract
95. Z.Yang, N.He, Q.Zhou. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol Cell Biol [Internet]. 2008;28(3):967–976 [cited 2016 Apr 11]. Available from: http://mcb.asm.org/content/28/3/967?ijkey=5e08476a45fa15be464ccd2435a3a3d3941eaa7c&keytype2=tf_ipsecsha
96. P.Filippakopoulos, J.Qi, S.Picaud, et al. Selective inhibition of BET bromodomains. Nature [Internet]. 2010;468(7327):1067–1073 [cited 2016 Apr 11]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3010259&tool=pmcentrez&rendertype=abstract
97. A.Ghoshal, D.Yugandhar, A.K.Srivastava. BET inhibitors in cancer therapeutics:a patent review. Expert Opin Ther Pat [Internet]. 2016;26(4):505–522 [cited 2016 May 3]. Available from: http://www.tandfonline.com/doi/abs/10.1517/13543776.2016.1159299
98. C.A.French. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol [Internet]. 2012;7:247–265 [cited 2016 Apr 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22017582
99. G.Schwartsmann, H.Schunemann, C.N.Gorini, et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs [Internet]. 2000;18(1):83–91 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10830142
100. P.Pohlmann, L.P.DiLeone, A.I.Cancella, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol [Internet]. 2002;25(5):496–501 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12393992
101. R.M.Glasspool, R.Brown, M.E.Gore, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2ʹ-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer [Internet]. 2014;110(8):1923–1929 [cited 2016 May 1]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3992493&tool=pmcentrez&rendertype=abstract
102. H.A.Tawbi, J.H.Beumer, A.A.Tarhini, et al. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma:a phase I/II study and pharmacokinetic analysis. Ann Oncol [Internet]. 2013;24(4):1112–1119 [cited 2016 Apr 15]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3603441&tool=pmcentrez&rendertype=abstract
103. S.S.Ramalingam, M.L.Maitland, P.Frankel, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol [Internet]. 2010;28(1):56–62 [cited 2016 Apr 12]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2799233&tool=pmcentrez&rendertype=abstract
104. J.Coronel, L.Cetina, I.Pacheco, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol [Internet]. 2011;28(Suppl 1):S540–6 [cited 2016 Apr 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20931299
105. M.Maio, A.Covre, E.Fratta, et al. Molecular pathways:at the crossroads of cancer epigenetics and immunotherapy. Clin Cancer Res [Internet]. 2015;21(18):4040–4047 [cited 2016 Apr 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26374074
106. L.Sigalotti, E.Fratta, S.Coral, et al. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther [Internet]. 2014;142(3):339–350. doi:10.1016/j.pharmthera.2013.12.015.
107. K.Odunsi, J.Matsuzaki, S.R.James, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res [Internet]. 2014;2(1):37–49 [cited 2016 Apr 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24535937
108. S.Jain, J.Zain, O.O’Connor, et al. Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol [Internet]. 2012;5(1):24 [cited 2016 Apr 15]. Available from: http://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-5-24
109. B.Coiffier, B.Pro, H.M.Prince, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma:pivotal study update demonstrates durable responses. J Hematol Oncol [Internet]. 2014;7:11 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24456586
110. H.-Z.Lee, V.E.Kwitkowski, P.L.Del Valle, et al. FDA approval:belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res [Internet]. 2015;21(12):2666–2670 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25802282
111. J.P.Laubach, P.Moreau, J.F.San-Miguel, et al. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res [Internet]. 2015;21(21):4767–4773 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26362997
112. J.F.San-Miguel, V.T.M.Hungria, S.-S.Yoon, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma:a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–1206.
113. U.Platzbecker, P.Fenaux. Personalized medicine in myelodysplastic syndromes:wishful thinking or already clinical reality? Haematologica [Internet]. 2015;100(5):568–571 [cited 2016 May 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25944636
114. P.Fenaux, G.J.Mufti, E.Hellstrom-Lindberg, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.